Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yaming Hang

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Antimicrobial Agents and Chemotherapy|March 21, 2012
Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patientsMatthew L Rizk, Yaming Hang, Wen-Lin Luo, et al.
Clinical Pharmacology and Therapeutics|February 21, 2023
Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ PerspectiveKosalaram Goteti, Nathan Hanan, Mindy Magee, et al.
Journal of Psychiatric Research|June 14, 2023
Altered brain function in patients with acrophobia: A voxel-wise degree centrality analysisMeilin Guo, Yuan Zhong, Jingren Xu, et al.
Clinical Pharmacology and Therapeutics|March 13, 2025
Establishment of a Biomarker-Directed Clinical Endpoint Model for Early-Stage Parkinson's Disease PatientsChurni Gupta, Chaejin Kim, Serge Guzy, et al.
Journal of Sleep Research|March 19, 2023
Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individualsRebecca Evans, Haruhide Kimura, Masato Nakashima, et al.
Journal of Psychiatry & Neuroscience : JPN|March 4, 2025
Impulse control deficits among patients with nonsuicidal self-injury: a mediation analysis based on structural imagingYa Xie, Sichu Wu, Jian Li, et al.
Anesthesiology|January 13, 2025
TAK-925 (Danavorexton), an Orexin Receptor 2 Agonist, Reduces Opioid-induced Respiratory Depression and Sedation without Affecting Analgesia in Healthy MenMaarten van Lemmen, Albert Dahan, Yaming Hang, et al.
The New England Journal of Medicine|May 14, 2025
Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1Yves Dauvilliers, Giuseppe Plazzi, Emmanuel Mignot, et al.
Comprehensive Psychiatry|May 7, 2024
Neural mechanism of non-adaptive cognitive emotion regulation in patients with non-suicidal self-injuryAuthor Nan Lang, Yuan Zhong, Wenkun Lei, et al.
Nature|June 23, 2017
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's diseaseJeff Sevigny, Ping Chiao, Thierry Bussière, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|March 21, 2012
Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patientsMatthew L Rizk, Yaming Hang, Wen-Lin Luo, et al.
Clinical Pharmacology and Therapeutics|February 21, 2023
Opportunities and Challenges of Disease Progression Modeling in Drug Development - An IQ PerspectiveKosalaram Goteti, Nathan Hanan, Mindy Magee, et al.
Journal of Psychiatric Research|June 14, 2023
Altered brain function in patients with acrophobia: A voxel-wise degree centrality analysisMeilin Guo, Yuan Zhong, Jingren Xu, et al.
Clinical Pharmacology and Therapeutics|March 13, 2025
Establishment of a Biomarker-Directed Clinical Endpoint Model for Early-Stage Parkinson's Disease PatientsChurni Gupta, Chaejin Kim, Serge Guzy, et al.
Journal of Sleep Research|March 19, 2023
Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individualsRebecca Evans, Haruhide Kimura, Masato Nakashima, et al.
Journal of Psychiatry & Neuroscience : JPN|March 4, 2025
Impulse control deficits among patients with nonsuicidal self-injury: a mediation analysis based on structural imagingYa Xie, Sichu Wu, Jian Li, et al.
Anesthesiology|January 13, 2025
TAK-925 (Danavorexton), an Orexin Receptor 2 Agonist, Reduces Opioid-induced Respiratory Depression and Sedation without Affecting Analgesia in Healthy MenMaarten van Lemmen, Albert Dahan, Yaming Hang, et al.
The New England Journal of Medicine|May 14, 2025
Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1Yves Dauvilliers, Giuseppe Plazzi, Emmanuel Mignot, et al.
Comprehensive Psychiatry|May 7, 2024
Neural mechanism of non-adaptive cognitive emotion regulation in patients with non-suicidal self-injuryAuthor Nan Lang, Yuan Zhong, Wenkun Lei, et al.
Nature|June 23, 2017
Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's diseaseJeff Sevigny, Ping Chiao, Thierry Bussière, et al.
Pageof 4